News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–5
Matches
5
Sources here
3
Companies here
1
Search results Stored financial headlines

Active search

5 matching headlines

Ticker or company: GRFMain company stories
Clear
Latest

finance.yahoo.com Earnings

FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.

FOXO Technologies Inc. WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.'s (OTC: FOXOD/FOXO) ( "FOXO") subsidiary, Vector BioSource, Inc. ("Vector") today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the "Agreement") from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is …

Grifols (GRFS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, July 28, 2026 at 12:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations and sustainability - Daniel SegarraChief Executive Officer - Nacho AbiaPresident of BioPharma - Roland WandelerChief Financial Officer - Rahul Srinivasan TAKEAWAYS Group Net Revenue …

GRF main company
Sharemaestro market context Price above Trend Line 52 weeks -20.5% GRF stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...

This article first appeared on GuruFocus. Revenue: EUR3,574 million for the first half, up 2.6% at constant currency. Biopharma Revenue Growth: 5.4% growth at constant currency. Adjusted EBITDA: EUR472 million in Q2, EUR854 million for the first half, with a margin of 25.2% in …

GRF main company
Sharemaestro market context Price above Trend Line 52 weeks -20.5% GRF stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. …

GRF main company
Sharemaestro market context Price above Trend Line 52 weeks -20.5% GRF stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context